大理药业(603963) - 2024 Q2 - 季度业绩预告

Financial Performance Expectations - The company expects a net profit attributable to shareholders of the parent company for the first half of 2024 to be between -14 million and -11 million RMB, indicating an increase in losses compared to the same period last year by 3.2176 million to 2.176 million RMB [2]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -16 million and -13 million RMB [2]. - In the same period last year, the net profit attributable to shareholders was -10.7824 million RMB, and the profit before tax was -8.9644 million RMB [4]. Reasons for Increased Losses - The main reason for the increased losses is the significant drop in sales prices of the company's main product, Xingnaojing injection, after winning the bid in the traditional Chinese medicine procurement, leading to reduced profit margins and lower sales volume [5]. - Although the company's other main product, Shenmai injection, saw a noticeable increase in sales in certain provinces, its overall revenue contribution remains limited due to low gross margins [5]. Forecast and Reporting - The company emphasizes that the performance forecast is based on preliminary calculations by its financial department and has not been audited by registered accountants [6]. - Investors are advised to consider the preliminary nature of the forecast data and await the official disclosure of the 2024 semi-annual report for accurate financial figures [7].